Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations (Unaudited)

v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development expenses $ 3,525,097 $ 3,197,532
General and administrative expenses 3,424,832 2,227,899
Total operating expenses 6,949,929 5,425,431
Loss from operations (6,949,929) (5,425,431)
Other income (expense):    
Interest income 111,757 82,183
Grant income 213,565
Change in fair value of warrant liability 254,955 825,989
Other income (expense) net: 580,277 908,172
Net loss $ (6,369,652) $ (4,517,259)
Net loss per share:    
Basic $ (0.14) $ (0.16)
Diluted $ (0.14) $ (0.16)
Weighted average common shares outstanding - basic 45,212,103 27,696,550
Weighted average common shares outstanding - diluted 45,212,103 27,696,550